The power and pitfalls of omics part 2: epigenomics, transcriptomics and ME/CFS
Simon McGrath concludes his blog about the remarkable Prof George Davey Smith's smart ideas for understanding diseases, which may soon be applied to ME/CFS.
Discuss the article on the Forums.

Status of Rituximab-ME/CFS Studies

Discussion in 'Rituximab: News and Research' started by Persimmon, Feb 15, 2012.

  1. lansbergen

    lansbergen Senior Member

    My guess: If new Tcells are spared from this they might work properly but it will take time to get enouigh healthy Tcells.
  2. liquid sky

    liquid sky Senior Member

    "Ocrelizumab has previously been investigated as a treatment for rheumatoid arthritis but studies were discontinued because of a high incidence of opportunistic infections in participants. Opportunistic infections are infections that do not normally occur in a healthy person but may occur when the immune system is compromised."

    This new B cell depletion drug, Ocrelizumab, has not been safer than Rituxan. Rituxan has been approved for years in RA with a good safety profile.

See more popular forum discussions.

Share This Page